Background: Psychotic symptoms such as delusion and hallucinations are common in people with dementia. They are associated with various deleterious outcomes including reduced quality of life and increased caregiver burden. Pharmacological interventions to combat psychotic symptoms have shown limited efficacy and can be associated with significant adverse events. Non-pharmacological interventions are recommended as the first line option for treatment, however there is a paucity of evidence for specific non-pharmacological options to primarily target psychotic symptoms in people with dementia. Further work is needed to identify, adapt and develop possible non-pharmacological options to target psychotic symptoms in dementia. Aim: To establish which non-pharmacological interventions could be used or adapted to treat psychotic symptoms and/or confer benefits in people with dementia Design: Modified Delphi consensus process. Two rounds of feedback were conducted and included a directed scoping review, based on the interventions recommended in the first round of the Delphi. Participants: An expert panel consisted of 12 members with clinical and research expertise in managing psychotic symptoms in people with dementia Results: There were three top nominated treatment options: cognitive behavioural therapy (CBT), family intervention, and personalized activities/environmental/sensory interventions, without a clear priority between the 3 approaches. The WHELD/Brief Psychosocial Therapy programme focussing on personalized activities improves concurrent neuropsychiatric symptoms in people with dementia related psychosis. Preliminary studies also suggest that combining personalized activities with family training may improve the direct impact on psychosis. There are also opportunities to adapt CBT interventions for people with psychosis related to early or mild dementia. Conclusions: There were clear recommendations for three non-pharmacological options that could be used or adapted to benefit people with psychosis in the context of dementia.

The authors have declared no competing interest.

This study was funded by the Bateman Family Foundation

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of University of Exeter College of Medicine and Health gave ethical approval of this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors